Dataset from A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009791
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to compare all-cause mortality at Day 14 in
participants receiving cefiderocol with participants receiving the comparator, meropenem, in
adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial
pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by
Gram-negative pathogens.
创建时间：
2024-11-27
